NVS - Our Chief Picks In Pharma
Pharma is well-known as an extremely high margin business, capable of generating substantial incremental shareholder value due to its capacity to leverage the economics of patents and its relatively low incremental investment rates. Indeed, the profitability of Pharma has made it a political target for decades. In the current environment, however, Pharma is proving to be a critical commercial pillar for bankrolling the research into COVID-19, with companies like Gilead (GILD) attempting to bring remdesivir to bear against the crisis. We are not interested in speculating on who will produce a coronavirus treatment